Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kawut, S. M.
Right arrow Articles by Barst, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawut, S. M.
Right arrow Articles by Barst, R. J.
(Chest. 2005;128:2355-2362.)
© 2005 American College of Chest Physicians

von Willebrand Factor Independently Predicts Long-term Survival in Patients With Pulmonary Arterial Hypertension*

Steven M. Kawut, MD, MS, FCCP; Evelyn M. Horn, MD; Ketevan K. Berekashvili, MD; Allison C. Widlitz, PA, MS; Erika B. Rosenzweig, MD and Robyn J. Barst, MD, FCCP

* From the Departments of Medicine (Drs. Kawut and Horn) and Pediatrics (Ms. Widlitz and Drs. Rosenzweig and Barst), College of Physicians and Surgeons, and the Department of Epidemiology (Dr. Berekashvili), Joseph L. Mailman School of Public Health, Columbia University, New York, NY.

Correspondence to: Steven Kawut, MD, MS, FCCP, Division of Pulmonary, Allergy, and Critical Care Medicine, PH 8E, Room 101, 622 W 168 St, New York, NY 10032; e-mail: sk2097{at}columbia.edu


   Abstract
TOP
 Abstract
Introduction
 Methods and Materials
 Results
 Discussion
 Conclusion
 References
 
Objectives: We hypothesized that higher plasma levels of von Willebrand factor (vWF) and reduced ristocetin cofactor activity (RCA)/vWF ratios at baseline and follow-up would be associated with an increased risk of death in patients with pulmonary arterial hypertension (PAH).

Background: Endothelial injury and dysfunction cause increased vWF levels in patients with cardiovascular disease. Increased vWF is associated with a higher risk of death in patients with coronary artery disease, congestive heart failure, and ARDS. In PAH, vWF is elevated and functions abnormally, resulting in reduced platelet binding. The ability of vWF to bind platelets is reflected by RCA.

Methods: We performed a retrospective cohort study of 66 PAH patients who underwent initial evaluation at our center from January 1994 to June 2002. The primary outcome was death or lung transplantation.

Results: vWF level was directly associated with Factor VIII activity, RCA, fibrinogen, and prothrombin time (p ≤ 0.01). vWF levels at baseline and follow-up were associated with the risk of death (hazard ratio [HR] per 50% increase, 1.4; 95% confidence interval [CI], 1.1 to 1.8 [p = 0.02]; and HR per 50% increase, 1.5; 95% CI, 1.1 to 2.0 [p = 0.011]; n = 48, respectively). RCA/vWF ratios were not associated with outcome. These results were unaffected by adjustment for demographics, baseline hemodynamics, laboratory results, or PAH therapy in multivariate analyses.

Conclusions: Increased vWF levels at baseline and follow-up are associated with worse survival in patients with PAH; however, RCA/vWF ratios are not. The hemostatic effects of vWF do not account for these findings. This suggests that endothelial injury and dysfunction may persist despite treatment and may impact on disease course. Therapies that target endothelial injury may therefore improve outcomes for patients with PAH.

Key Words: cohort study • endothelial dysfunction • pulmonary hypertension • ristocetin cofactor • survival • von Willebrand factor


   Introduction
TOP
 Abstract
 Introduction
Methods and Materials
 Results
 Discussion
 Conclusion
 References
 
Pulmonary arterial hypertension (PAH) is characterized by disordered endothelial cell and smooth-muscle proliferation in the small muscular pulmonary arteries. Endothelial dysfunction and injury have become important features of the pathobiology of this disease.1 Two components of endothelial dysfunction, eicosanoid imbalance and elevated endothelin-1, have provided the rationale for the clinical development of prostacyclin analogues and endothelin-1 receptor antagonists as important therapeutic interventions for PAH.234567

In addition to regulating vasoactivity and cellular mitogenesis, the endothelium also modulates local hemostasis. von Willebrand factor (vWF) is a multimeric glycoprotein that is stored in the Weibel-Palade bodies of vascular endothelium and, to a lesser extent, in {alpha} granules of platelets. Released after endothelial perturbation, functional vWF multimers bind to exposed collagen in areas of vascular injury and initiate platelet plug formation. The ristocetin cofactor activity (RCA)/vWF ratio reflects the relative platelet-binding activity of vWF. vWF also contributes to thrombogenesis by stabilizing Factor VIII and preserving its function. vWF levels are elevated in PAH, and RCA/vWF ratios are reduced. We hypothesized that a higher vWF level and a lower RCA/vWF ratio at baseline would predict an increased risk of death in patients with PAH. We also hypothesized that persistent abnormalities in these measures despite treatment would be associated with poor outcomes.


   Methods and Materials
TOP
 Abstract
 Introduction
 Methods and Materials
Results
 Discussion
 Conclusion
 References
 
Study Design
We performed a retrospective cohort study of all consecutive adult patients with PAH who underwent initial evaluation from January 1994 to June 2002 with follow-up through June 2003 at the New York Presbyterian Pulmonary Hypertension Center. Details of the cohort have been published elsewhere.8 The cohort included patients > 16 years of age with PAH (idiopathic, familial, or associated with anorexigen use) evaluated during the study period. Patients routinely underwent laboratory testing and cardiac catheterization at baseline evaluation. Acute vasoreactivity with short-acting vasodilators was defined as a decrease in mean pulmonary artery pressure of ≥ 20% without a decrease in cardiac index.9

The primary combined end point was death or lung transplantation. A patient was censored as alive at the last medical contact recorded in the computerized clinical database through June 2003. Choice of therapy was consistent with consensus algorithms.10 Although not all therapies were available throughout the study period, we adjusted for these differences in the analysis. The study was approved by the Columbia University Institutional Review Board.

Laboratory Analysis
vWF levels were measured using the Laurell rocket method1112 from 1994 until 1997, and the immunoturbidimetric method (STA-Liatest; Diagnostica Stago; Asnières sur Seine, France) from 1997 until 2002. vWF is expressed as the percentage of normal control (normal < 150%). The Ristocetin Cofactor Assay Kit (Helena Laboratories; Beaumont, TX) was used to measure the agglutination of formalin-fixed normal platelets by ristocetin after the addition of test plasma. Results range from 20 to 120% activity. The normal RCA/vWF ratio is > 0.80. Factor VIII activity was measured by the ability of the sample to correct the activated partial thromboplastin time of factor VIII-deficient plasma (IL ACL 3000; Instrumentation Laboratory; Lexington, MA).

Statistical Analysis
Continuous variables were summarized by the mean ± SD or median (range). Categorical variables were summarized by frequencies with 95% confidence interval (CIs). Spearman {rho} was used for correlations with the Bonferroni correction for each variable of interest (ie, vWF and RCA/vWF ratio). Survival analysis was performed using the Kaplan-Meier estimator and the log-rank test. We used Cox proportional hazards models to analyze the association of each variable of interest with survival utilizing time-varying covariates.13 This statistical method allows the analysis of repeated measurements of vWF and controls for the use of different therapies over the course of the study period.

Multivariate models were constructed using vWF and the RCA/vWF ratio as the primary risk factors of interest. Potential confounders were added to the models to assess the impact on the effect estimates. A change of > 20% in the coefficient of the risk factor was considered to indicate confounding. All analyses were performed with available data. The proportional hazards assumption and the presence of influential subjects were assessed. p Values < 0.05 were considered statistically significant. Analyses were performed using statistical software (Stata 7.0; Stata Corporation; College Station, TX).


   Results
TOP
 Abstract
 Introduction
 Methods and Materials
 Results
Discussion
 Conclusion
 References
 
The initial cohort was composed of 84 patients with newly diagnosed PAH. Eighteen patients who had missing data for vWF, RCA, Factor VIII, and/or right-heart catheterization were excluded. Patients with missing data were not significantly different from those in the final cohort (n = 66) in terms of the date of evaluation, demographics, etiology of PAH, baseline hemodynamics, or survival.

The characteristics of the final cohort are shown in Table 1 . Twenty-nine patients (44%) were treated with IV epoprostenol, 12 patients (18%) received subcutaneous treprostinil, 21 patients (32%) received oral bosentan, and 26 patients (39%) received calcium-channel blockers. Most patients (90%) were treated with more than one therapy simultaneously or sequentially. The median follow-up was 833 days (range, 4 to 3,365 days). Eighteen patients died, and 1 patient underwent lung transplantation. Transplant-free survival was 91% (95% CI, 80 to 96%) at 1 year and 62% (95% CI, 43 to 76%) at 5 years.


View this table:
[in this window]
[in a new window]

  		Table 1.. Baseline Demographic, Hemodynamic, and Laboratory Data (n = 66)*

 
Thirty patients (45%) had abnormally high (> 150%) vWF levels, and 43 patients (65%) had abnormally low (< 0.80) RCA/vWF ratios at baseline. vWF directly correlated with RCA ({rho} = 0.55, p < 0.001), Factor VIII activity ({rho} = 0.75, p < 0.001), fibrinogen ({rho}= 0.40, p = 0.01) [n = 65], and prothrombin time ({rho} = 0.44, p = 0.005) [n = 65]. The RCA/vWF ratio was inversely associated with Factor VIII activity ({rho} = – 0.48, p < 0.002) and prothrombin time ({rho} = – 0.46, p < 0.002) [n = 65]. There were no associations between vWF or RCA/vWF ratio and age, gender, ethnicity, race, body mass index, baseline hemodynamics, or other laboratory results (data not shown).

Survival Analysis
A higher vWF level at baseline predicted an increased risk of death (Table 2 ). The hazard ratio (HR) for vWF was unchanged regardless of adjustment for multiple other variables, demonstrating lack of confounding by these factors. As no acutely vasoreactive patients died or underwent transplantation, we were unable to adjust for acute vasoreactivity. However, stratified analysis of only patients who were nonreactive (n = 50) [or who did not have acute vasodilators administered, n = 6] also showed an association between vWF and the risk of death (HR per 50% increase, 1.32; 95% CI, 1.02 to 1.71; p = 0.036), minimizing the possibility of confounding by acute vasoreactivity. As Factor VIII may mediate the effect of vWF on survival via thrombogenesis, this factor should not be considered a confounder. Nonetheless, the HR for vWF after adjustment for Factor VIII was 1.93 (95% CI, 1.29 to 2.87; p = 0.001).


View this table:
[in this window]
[in a new window]

  		Table 2.. Association of Baseline vWF Level With the Risk of Death or Transplantation

 
Patients with baseline vWF levels > 220% (a cutoff used in a previous study14) had a dramatically increased risk of death (HR, 3.97; 95% CI, 1.52 to 10.4; p = 0.005) [Fig 1 ]. This association persisted despite adjustment for sex, race, ethnicity, baseline hemodynamics, other laboratory values, and treatment (data not shown). Outcomes were not associated with the baseline RCA/vWF ratio (HR per 0.10 decrease, 1.10; 95% CI, 0.95 to 1.27; p = 0.19), baseline RCA (HR per 10% increase, 1.09; 95% CI, 0.92 to 1.30; p = 0.33), or baseline Factor VIII level (HR per 50% increase, 1.03; 95% CI, 0.81 to 1.32; p = 0.79).



View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1.. Kaplan-Meier estimator of transplant-free survival by vWF level at baseline.

 
Forty-eight patients from the cohort had vWF assessments repeated after initiation of therapy. The median follow-up time in this subset was 1,305 days (range, 147 to 3,365 days) with repeat assays assessed on average 2.9 ± 1.0 times (± SD) per patient. Therapies used were similar to those in the entire cohort. Patients who were reassessed had a better survival compared to those who were not (p = 0.02), whereas age, gender, and baseline hemodynamics were similar between the groups (p > 0.10).

Elevated vWF levels at baseline and follow-up were associated with an increased risk of death in bivariate and multivariate analyses (Table 3 ). Stratified analysis of patients who did not show acute reactivity to vasodilators (n = 33) [or who were not tested, n = 6] showed similar results (HR, 1.41; 95% CI, 1.06 to 1.87; p = 0.0017). Adjustment for calcium-channel blocker use could not be performed, since no patients treated with calcium-channel blockers died during the study period. A vWF level > 220% over time was associated with a significantly increased risk of death (HR, 4.71; 95% CI, 1.14 to 19.39; p = 0.032) [Fig 2 ], which was not affected by adjustment for other variables (data not shown). The HR for vWF over time after adjustment for Factor VIII activity was 1.40 (95% CI, 0.99 to 1.98; p = 0.06).


View this table:
[in this window]
[in a new window]

  		Table 3.. Association of vWF Level Over Time With the Risk of Death or Transplantation

 


View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2.. Kaplan-Meier estimator of transplant-free survival by vWF levels at baseline and follow-up.

 
Although a persistently low RCA/vWF ratio over time may have been associated with an increased risk of death in bivariate analysis (Table 4 ), this was not statistically significant and may have been confounded by other factors. Neither RCA (HR per 10% increase, 1.09; 95% CI, 0.88 to 1.35; p = 0.45) nor Factor VIII activity (HR per 50% increase, 1.29; 95% CI, 0.98 to 1.69; p = 0.07) over time were associated with the risk of death.


View this table:
[in this window]
[in a new window]

  		Table 4.. Association of RCA/vWF Ratio Over Time With the Risk of Death or Transplantation

 
We repeated the survival analysis including only patients with idiopathic PAH (n = 51) or idiopathic and familial PAH (n = 62); the results were unchanged. Adjustment for the type of vWF assay used or the date of baseline evaluation did not significantly alter the conclusions. Both vWF levels and the RCA/vWF ratios met the assumption of proportional hazards. There were no particularly influential subjects.


   Discussion
TOP
 Abstract
 Introduction
 Methods and Materials
 Results
 Discussion
Conclusion
 References
 
We have shown for the first time a significant association between increased vWF and worse outcome in PAH (idiopathic, familial, or related to anorexigen use). This relationship persisted (ie, the HRs were unchanged or increased) after adjustment for multiple potential confounding variables and variations in assumptions. Although a reduced RCA/vWF ratio over time may be associated with a higher risk of death, this finding was not statistically significant and may have been confounded, as the HR significantly decreased after adjustment for certain factors (eg, erythrocyte sedimentation rate and fibrinogen).

We and others15161718 have previously shown that patients with PAH have increased circulating levels of vWF with reduced platelet binding. Lopes et al181920 attributed the reduced biological activity of vWF in PAH to hyposialylated subunits with loss of the normal multimeric structure and an increase in smaller molecules. High-molecular-weight vWF multimers bind more tightly to platelet receptors and increase signaling through crosslinking.212223

We have also previously shown a significant decrease in vWF levels and increase in RCA/vWF ratios in a small group of PAH patients treated with IV epoprostenol for 1 year.15 Veyradier et al24 demonstrated a decrease in vWF levels to near normal, partial restoration of the high- to low-molecular-weight multimer ratio, and a decrease in proteolytic fragments after treatment with IV epoprostenol for 30 days. These studies demonstrate the responsiveness of endothelial injury and vWF release to IV epoprostenol therapy in select patients. This may be due to a direct effect of epoprostenol on the pulmonary or systemic endothelium or an epiphenomenon of improved cardiopulmonary hemodynamics.

Lopes et al142526 have shown that patients with idiopathic PAH (n = 11) have higher vWF levels than patients with other etiologies of PAH (eg, PAH related to congenital heart disease) or patients with pulmonary hypertension associated with schistosomiasis. However, these studies142526 did not show statistically significant associations between vWF levels and survival in the patients with idiopathic PAH.

vWF is a strong and independent risk factor for coronary artery disease and venous thromboembolism in healthy subjects and for cardiovascular events in patients with known coronary artery disease.27282930 Several studies28313233 have shown associations between increased vWF and the risk of death in healthy subjects and patients with coronary artery disease, congestive heart failure, or ARDS. We have now shown that increased vWF levels predict the risk of death in PAH as well.

The systemic inflammatory milieu, hypercoagulable state, and/or endothelial injury may explain these findings. Systemic inflammation with cytokine up-regulation and increased neutrophil reactivity is present in patients with PAH.34353637383940 As vWF is an acute-phase reactant, increased levels in PAH may merely reflect worse systemic inflammation. However, this is unlikely in our cohort, as adjustment for other markers of systemic inflammation, such as fibrinogen, erythrocyte sedimentation rate, and platelet count, did not change the results. In addition, unlike vWF, these variables were not associated with survival (data not shown). Shear stress increases proteolysis of vWF.41 While worse hemodynamics and increased shear stress in PAH could account for the relationship between vWF and outcome, adjustment for hemodynamic parameters at baseline did not significantly change the results.

Higher vWF levels may cause in situ thrombosis in PAH. vWF contributes to clot formation in two ways. vWF binds to exposed subendothelial collagen at sites of vascular injury and subsequently to platelet Ib-IX-V and IIb-IIIa receptors, recruiting and activating platelets. vWF also stabilizes and activates Factor VIII. However, our findings do not support a thrombogenic mechanism for vWF in PAH. Neither absolute nor relative RCA (which reflect potential for platelet aggregation) were associated with survival. Adjustment for Factor VIII levels in our analysis did not change our results, making it less likely that Factor VIII mediates the increased risk of death conferred by elevated vWF.

Circulating vWF most likely reflects the severity of endothelial injury and dysfunction, which may independently impact on event-free survival. A recent study42 in congestive heart failure has shown associations with other measures of endothelial perturbation, such as flow-mediated dilatation and circulating endothelial cells. The strong association between baseline vWF and outcome, despite treatment with prostacyclin analogues or the endothelin-1 receptor antagonist bosentan, suggests that there are factors beyond eicosanoid metabolism and endothelin-1 at the time of PAH diagnosis that are integral to disease progression. As in atherosclerotic heart disease and congestive heart failure, specific therapies that target endothelial dysfunction by distinct pathways may be important adjunctive therapy for this disease. Results from studies in animal models of PAH treated with 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors support such an approach.434445 Evidence of improvement in endothelial dysfunction with angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors provides a rationale for conducting randomized clinical trials of these agents in patients with PAH.464748 If validated, vWF could be useful as a surrogate end point in such studies.4950

Limitations
The original vWF assay used in the early years of this cohort was subsequently replaced by a more current technique. Despite this change, the reference values for vWF were standardized normals, and adjustment for the different methods utilized did not affect the results. In addition, such a change would be expected to introduce measurement variability, if anything, biasing the results to the null. These data do not elucidate the source of vWF in PAH. While platelet degranulation is possible, evidence from many other diseases makes an endothelial source much more likely. While there were some missing data, we found no significant differences between patients in the final cohort and those who were excluded, making selection bias unlikely. Patients who had multiple assessments over time not surprisingly had a better survival than those who did not. This likely reflects the lower severity of illness of those who lived long enough to be reassessed. While assessments were not performed at standard times or in relation to changes in therapy, we used time-varying analyses to account for this variability.


   Conclusion
TOP
 Abstract
 Introduction
 Methods and Materials
 Results
 Discussion
 Conclusion
References
 
Endothelial injury is important in the pathobiology of PAH. Increased vWF levels at baseline and follow-up are strong predictors of outcome despite controlling for other known determinants of survival. Current therapies may not fully address this aspect of disease activity. Future work should focus on the implications of and targeted treatments for endothelial dysfunction in PAH.


   Acknowledgements
 
We thank the personnel of the Special Coagulation Laboratory at the New York Presbyterian Hospital for their assistance.


   Footnotes
 
Abbreviations: CI = confidence interval; HR = hazard ratio; PAH = pulmonary arterial hypertension; RCA = ristocetin co-factor activity; vWF = von Willebrand factor

Dr. Kawut has received funding from Actelion Pharmaceuticals, Ltd. and Pfizer, Inc. Drs. Horn, Rosenzweig, and Barst, and Ms. Widlitz have received funding from Actelion Pharmaceuticals, Ltd., Pfizer, Inc., United Therapeutics Corporation, Encysive Pharmaceuticals, Inc., INO Therapeutics, Inc., CoTherix, Inc., Myogen, Inc., and Medtronic, Inc.

This work was supported by National Institutes of Health grant HL67771 and the Florence and Herbert Irving Clinical Research Career Award.

Received for publication December 21, 2004. Accepted for publication April 13, 2005.


   References
TOP
 Abstract
 Introduction
 Methods and Materials
 Results
 Discussion
 Conclusion
 References
 

  1. Budhiraja, R, Tuder, RM, Hassoun, PM (2004) Endothelial dysfunction in pulmonary hypertension. Circulation 109,159-165[Free Full Text]
  2. Christman, BW, McPherson, CD, Newman, JH, et al An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327,70-75[Abstract]
  3. Barst, RJ, Rubin, LJ, Long, WA, et al A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334,296-302[Abstract/Free Full Text]
  4. Rubin, LJ, Badesch, DB, Barst, RJ, et al Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346,896-903[Abstract/Free Full Text]
  5. Barst, RJ, Langleben, D, Frost, A, et al Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169,441-447[Abstract/Free Full Text]
  6. Olschewski, H, Simonneau, G, Galie, N, et al Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347,322-329[Abstract/Free Full Text]
  7. Simonneau, G, Barst, RJ, Galie, N, et al Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165,800-804[Abstract/Free Full Text]
  8. Kawut, SM, Horn, EM, Berekashvili, KK, et al New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005;95,199-203[CrossRef][ISI][Medline]
  9. Barst, RJ, Maislin, G, Fishman, AP Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999;99,1197-1208[Abstract/Free Full Text]
  10. Galie, N, Seeger, W, Naeije, R, et al Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43,81S-88S[Abstract/Free Full Text]
  11. Laurell, CB Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966;15,45-52[CrossRef][ISI][Medline]
  12. Zimmerman, TS, Hoyer, LW, Dickson, L, et al Determination of the von Willebrand’s disease antigen (factor VIII-related antigen) in plasma by quantitative immunoelectrophoresis. J Lab Clin Med 1975;86,152-159[ISI][Medline]
  13. Cox, DR Regression models and life tables (with discussion). J R Stat Soc 1972;34,187-220
  14. Lopes, AA, Maeda, NY, Bydlowski, SP Abnormalities in circulating von Willebrand factor and survival in pulmonary hypertension. Am J Med 1998;105,21-26[CrossRef][ISI][Medline]
  15. Friedman, R, Mears, JG, Barst, RJ Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997;96,2782-2784[Abstract/Free Full Text]
  16. Hoeper, MM, Sosada, M, Fabel, H Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 1998;12,1446-1449[Abstract]
  17. Rabinovitch, M, Andrew, M, Thom, H, et al Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 1987;76,1043-1052[Abstract/Free Full Text]
  18. Lopes, AA, Maeda, NY, Aiello, VD, et al Abnormal multimeric and oligomeric composition is associated with enhanced endothelial expression of von Willebrand factor in pulmonary hypertension. Chest 1993;104,1455-1460[Abstract/Free Full Text]
  19. Lopes, AA, Ferraz de Souza, B, Maeda, NY Decreased sialic acid content of plasma von Willebrand factor in precapillary pulmonary hypertension. Thromb Haemost 2000;83,683-687[ISI][Medline]
  20. Lopes, AA, Maeda, NY Abnormal degradation of von Willebrand factor main subunit in pulmonary hypertension. Eur Respir J 1995;8,530-536[Abstract]
  21. Arya, M, Anvari, B, Romo, GM, et al Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 2002;99,3971-3977[Abstract/Free Full Text]
  22. Kasirer-Friede, A, Ware, J, Leng, L, et al Lateral clustering of platelet GP Ib-IX complexes leads to up-regulation of the adhesive function of integrin{alpha} Iibß3. J Biol Chem 2002;277,11949-11956[Abstract/Free Full Text]
  23. Ruggeri, ZM Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 2001;14,257-279[Medline]
  24. Veyradier, A, Nishikubo, T, Humbert, M, et al Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension. Circulation 2000;102,2460-2462[Abstract/Free Full Text]
  25. Lopes, AA, Maeda, NY, Goncalves, RC, et al Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. Am Heart J 2000;139,618-623[ISI][Medline]
  26. Lopes, AA, Maeda, NY Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension. Chest 1998;114,1276-1282[Abstract/Free Full Text]
  27. Thompson, SG, Kienast, J, Pyke, SD, et al Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332,635-641[Abstract/Free Full Text]
  28. Folsom, AR, Wu, KK, Rosamond, WD, et al Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997;96,1102-1108[Abstract/Free Full Text]
  29. Morange, PE, Simon, C, Alessi, MC, et al Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004;109,1343-1348[Abstract/Free Full Text]
  30. Tsai, AW, Cushman, M, Rosamond, WD, et al Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002;113,636-642[CrossRef][ISI][Medline]
  31. Ware, LB, Eisner, MD, Thompson, BT, et al Significance of von Willebrand factor in septic and non-septic patients with acute lung injury. Am J Respir Crit Care Med 2004;170,766-772[Abstract/Free Full Text]
  32. Ware, LB, Conner, ER, Matthay, MA von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med 2001;29,2325-2331[CrossRef][ISI][Medline]
  33. Chin, BS, Conway, DS, Chung, NA, et al Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis 2003;14,515-521[CrossRef][ISI][Medline]
  34. Balabanian, K, Foussat, A, Dorfmuller, P, et al CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165,1419-1425[Abstract/Free Full Text]
  35. Dorfmuller, P, Zarka, V, Durand-Gasselin, I, et al Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165,534-539[Abstract/Free Full Text]
  36. Humbert, M, Monti, G, Brenot, F, et al Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151,1628-1631[Abstract]
  37. Humbert, M, Monti, G, Fartoukh, M, et al Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;11,554-559[Abstract]
  38. Fartoukh, M, Emilie, D, Le Gall, C, et al Chemokine macrophage inflammatory protein-1{alpha} mRNA expression in lung biopsy specimens of primary pulmonary hypertension. Chest 1998;114,50S-51S[ISI][Medline]
  39. Dorfmuller, P, Perros, F, Balabanian, K, et al Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22,358-363[Abstract/Free Full Text]
  40. Rose, F, Hattar, K, Gakisch, S, et al Increased neutrophil mediator release in patients with pulmonary hypertension: suppression by inhaled iloprost. Thromb Haemost 2003;90,1141-1149[ISI][Medline]
  41. Tsai, HM Shear stress and von Willebrand factor in health and disease. Semin Thromb Haemost 2003;29,479-488[CrossRef][ISI][Medline]
  42. Chong, AY, Blann, AD, Patel, J, et al Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 2004;110,1794-1798[Abstract/Free Full Text]
  43. Nishimura, T, Vaszar, LT, Faul, JL, et al Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003;108,1640-1645[Abstract/Free Full Text]
  44. Nishimura, T, Faul, JL, Berry, GJ, et al Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002;166,1403-1408[Abstract/Free Full Text]
  45. Girgis, RE, Li, D, Zhan, X, et al Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003;285,H938-H945[Abstract/Free Full Text]
  46. Mancini, GB, Henry, GC, Macaya, C, et al Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996;94,258-265[Abstract/Free Full Text]
  47. O’Driscoll, G, Green, D, Rankin, J, et al Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997;100,678-684[ISI][Medline]
  48. O’Driscoll, G, Green, D, Taylor, RR Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95,1126-1131[Abstract/Free Full Text]
  49. Kawut, SM, Palevsky, HI Surrogate end points in pulmonary arterial hypertension. Am Heart J 2004;148,559-565[CrossRef][ISI][Medline]
  50. Peacock, A, Naeijie, R, Galie, N, et al End points in pulmonary arterial hypertension: the way forward. Eur Respir J 2004;23,947-953[Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kawut, S. M.
Right arrow Articles by Barst, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawut, S. M.
Right arrow Articles by Barst, R. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS